Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Net Cash Flow (2019 - 2025)

AVITA Medical (RCEL) has disclosed Net Cash Flow for 5 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 12.86% year-over-year to -$5.2 million, compared with a TTM value of -$3.8 million through Dec 2025, up 52.81%, and an annual FY2025 reading of -$3.8 million, up 52.81% over the prior year.
  • Net Cash Flow was -$5.2 million for Q4 2025 at AVITA Medical, down from $3.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $13.4 million in Q3 2023 and bottomed at -$32.0 million in Q1 2022.
  • Average Net Cash Flow over 4 years is -$2.8 million, with a median of -$1.1 million recorded in 2024.
  • The sharpest move saw Net Cash Flow soared 220.54% in 2023, then plummeted 629.74% in 2025.
  • Year by year, Net Cash Flow stood at -$5.7 million in 2022, then crashed by 404.57% to -$28.7 million in 2023, then surged by 84.03% to -$4.6 million in 2024, then fell by 12.86% to -$5.2 million in 2025.
  • Business Quant data shows Net Cash Flow for RCEL at -$5.2 million in Q4 2025, $3.2 million in Q3 2025, and -$2.7 million in Q2 2025.